Want to see NGEN full AI Analyst Report?

NervGen Pharma (NGEN) Price & Analysis

120 Followers

NGEN Stock Chart & Stats

$4.07

$0.00(0.00%)

At close: Jan 08 4:00 PM EST

$4.07

$0.00(0.00%)

Day’s Range― - ―

52-Week Range$1.58 - $6.30

Previous CloseN/A

VolumeN/A

Average Volume (3M)818.53K

Market Cap

$133.15M

Enterprise Value$289.36

Total Cash (Recent Filing)$16.55M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta0.50

Next Earnings

Aug 12, 2026

EPS Estimate

-0.06

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.65

Shares Outstanding82,193,140

10 Day Avg. Volume880,572

30 Day Avg. Volume818,526

Financial Highlights & Ratios

PEG Ratio-0.18

Price to Book (P/B)159.85

Price to Sales (P/S)0.00

P/FCF Ratio-28.50

Enterprise Value/Market Cap<0.01

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-0.02

Enterprise Value/Ebitda>-0.01

Forecast

1Y Price Target

$10.33

Price Target Upside153.89% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering4

EPS Forecast (FY)-0.24

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Objective Phase 1b/2a Efficacy SignalIndependently blinded biomechanical gait analyses showed a multivariate treatment effect and responder classification for all NVG-291 recipients versus 10% on placebo. Objective multi-domain signals (gait, electrophysiology, hand function) materially strengthen the program’s clinical differentiation and long-term potential as a first-in-class neuroreparative therapy, improving the probability that late‑stage trials yield meaningful regulatory endpoints and durable competitive advantage.

Regulatory Alignment And Phase 3 PathFDA End-of-Phase 2 alignment and a planned registrational RESTORE trial reduce development path ambiguity and execution risk. A clear regulatory roadmap with site activation underway supports organized resource allocation, faster de‑risking through pivotal data, and better long-term strategic planning for label definition and subsequent indication expansion.

Demonstrated Access To Capital MarketsA successful $60M underwritten offer (and subsequent ATM filing) shows institutional market access to fund clinical development. Combined with minimal debt on the balance sheet, proven equity access extends the company’s runway, allowing continued investment in registrational studies and program expansion without immediate revenue, which is critical for clinical‑stage biotech durability.

Bears Say

Pre-revenue With Widening LossesNervGen has no product revenue and sustained growing operating losses (from approximately -$12.8M in 2021 to -$44.1M in 2025 and -$46.7M TTM). This persistent unprofitability means long-term value depends entirely on clinical and regulatory success, increasing execution risk and making funding and milestone delivery critical to preserve enterprise value.

High And Accelerating Cash BurnOperating cash outflows have increased meaningfully, with free cash flow tracking losses and TTM burn near -$27.5M. Q1 2026 cash fell to $16.6M, underscoring constrained runway absent further financings. Sustained negative cash generation pressures timing of pivotal trials and forces prioritization of programs or reliance on dilutive capital markets activity.

Ongoing Reliance On Dilutive Equity FinancingRepeated equity raises and an at-the-market facility indicate structural dependence on dilutive financings to fund development. Historical equity volatility and a prior negative equity period highlight funding sensitivity; ongoing dilution risk can constrain long-term shareholder returns and requires consistent market access to sustain clinical programs.

NervGen Pharma News

NervGen Pharma price target lowered to $15 from $18 at H.C. Wainwright

H.C. Wainwright analyst Raghuram Selvaraju lowered the firm’s price target on NervGen Pharma (NGEN) to $15 from $18...

21d ago

NGEN

NervGen Pharma initiated with an Outperform at Leerink

Leerink analyst Marc Goodman initiated coverage of NervGen Pharma (NGEN) with an Outperform rating and $10 price target...

22d ago

NGEN

NervGen Pharma Sets Up US$50 Million ATM Equity Program With Leerink Partners

NervGen Pharma ( ($NGEN) ) has issued an update. On July 2, 2026, NervGen Pharma filed a Form...

1M ago

NGEN

NervGen Pharma initiated with a Buy at TD Cowen

TD Cowen initiated coverage of NervGen Pharma (NGEN) with a Buy rating and no price target The company...

2M ago

NGEN

NervGen Pharma Raises US$60 Million in Underwritten Offering to Fund NVG-291 Program

NervGen Pharma ( ($NGEN) ) has shared an announcement. On May 21, 2026, NervGen Pharma priced an underwritten...

2M ago

NGEN

Nervgen’s CONNECT Trial Termination: What It Means for NGEN Investors

Nervgen Pharma Corp ($NGEN) announced an update on their ongoing clinical study. The CONNECT study, officially titled “A...

2M ago

NGEN

NervGen Reports Objective Neural Recovery Signal for NVG-291 in Chronic SCI Ahead of Phase 3

NervGen Pharma ( ($NGEN) ) has provided an update. On May 26, 2026, NervGen Pharma reported independently conducted,...

2M ago

NGEN

NervGen Pharma files $250M mixed securities shelf

09:28 EDT NervGen Pharma (NGEN) files $250M mixed securities shelf Published first on TheFly – the ultimate source...

2M ago

NGEN

NervGen Pharma announces biomechanical gait analyses on recovery with NVG-291

NervGen Pharma (NGEN) announced positive independent, blinded biomechanical gait analyses demonstrating genuine neural recovery with NVG-291 in the...

2M ago

NGEN

NervGen Pharma Launches Underwritten Public Offering to Fund NVG-291 Development

NervGen Pharma ( ($NGEN) ) has shared an announcement. On May 21, 2026, NervGen Pharma announced it had...

2M ago

NGEN

NervGen Pharma 24M share Spot Secondary priced at $2.50

Leerink and TD Cowen acted as joint book running managers for the offering. Published first on TheFly –...

2M ago

NGEN

NervGen Pharma secondary being re-offered at $2.50 per share

Leerink Partners and TD Cowen are acting as joint bookrunning managers for the offering. Published first on TheFly...

2M ago

NGEN

NervGen Pharma announces common share offering, no amount given

NervGen Pharma (NGEN) Corp. announced that it has commenced an underwritten public offering of common shares and accompanying...

3M ago

NGEN

NervGen Pharma Advances NVG-291 Toward Registrational Trial as Q1 2026 Loss Narrows

NervGen Pharma ( ($NGEN) ) has provided an announcement. NervGen Pharma reported first-quarter 2026 results on May 18,...

3M ago

NGEN

NGEN FAQ

What was Nervgen Pharma Corp’s price range in the past 12 months?

Nervgen Pharma Corp lowest stock price was $1.58 and its highest was $6.30 in the past 12 months.

What is Nervgen Pharma Corp’s market cap?

Nervgen Pharma Corp’s market cap is $133.15M.

When is Nervgen Pharma Corp’s upcoming earnings report date?

Nervgen Pharma Corp’s upcoming earnings report date is Aug 12, 2026 which is in 8 days.

How were Nervgen Pharma Corp’s earnings last quarter?

Currently, no data Available

Is Nervgen Pharma Corp overvalued?

According to Wall Street analysts Nervgen Pharma Corp’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Nervgen Pharma Corp pay dividends?

Nervgen Pharma Corp does not currently pay dividends.

What is Nervgen Pharma Corp’s EPS estimate?

Nervgen Pharma Corp’s EPS estimate is -0.06.

How many shares outstanding does Nervgen Pharma Corp have?

Nervgen Pharma Corp has 82,193,140 shares outstanding.

What happened to Nervgen Pharma Corp’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Nervgen Pharma Corp?

Currently, no hedge funds are holding shares in NGEN

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

NervGen Pharma Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

35.21%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Nervgen Pharma Corp

NervGen Pharma Corp. is a biotechnology enterprise currently in its clinical development phase, focused on devising therapeutic solutions for nerve injuries and progressive neurodegenerative diseases. Their innovative approach centers on deactivating the natural biological mechanisms that typically impede the nervous system's ability to repair itself.

NervGen Pharma (NGEN) Earnings & Revenues

Historic Earnings Reports

NGEN Stock 12 Month Forecast

Average Price Target

$10.33

▲(153.89% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","4":"$4","8":"$8","12":"$12","16":"$16"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":15,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$15.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10.333333333333332,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$10.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$6.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,4,8,12,16],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.62,2.649230769230769,3.6784615384615384,4.707692307692308,5.736923076923077,6.766153846153846,7.795384615384616,8.824615384615385,9.853846153846153,10.883076923076924,11.912307692307692,12.94153846153846,13.970769230769232,{"y":15,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.62,2.2902564102564105,2.9605128205128204,3.6307692307692303,4.301025641025641,4.971282051282051,5.6415384615384605,6.311794871794871,6.982051282051281,7.652307692307692,8.322564102564101,8.992820512820511,9.663076923076922,{"y":10.333333333333332,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.62,1.956923076923077,2.293846153846154,2.630769230769231,2.9676923076923076,3.304615384615385,3.641538461538462,3.9784615384615387,4.315384615384616,4.6523076923076925,4.989230769230769,5.326153846153846,5.663076923076924,{"y":6,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.46,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.597,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.524,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.48,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.14,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.6,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.18,"date":1769904000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":4.16,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.36,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.78,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.94,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.09,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.62,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >